

Commissioned Research

30 September 2024

Results Preview

Fair value range: EUR8.6–10.4

Share price: EUR7.3

Research analysts:

Jakob Söderblom Johan Wettergren Finland

Technology Hardware & Equipment

Scanfil

Demand remains murky, focus on outlook – Q3 preview

No signs yet of market sentiment improving

Similar to Q2(24), when Scanfil's sales dropped ~19% Y/Y organically, we expect Q3 to have been another quarter of murky market sentiment adversely impacted by general uncertainty and lingering destocking. We model Scanfil to report net sales of EUR173m in Q3(24), corresponding to an organic decline of 19%, with weak European industrial markets as the large sinker. Still, we expect some continued improvement among Scanfil's Medtech & Life Science customers, as highlighted both by the company in Q2 and in our recently conducted demand survey. We expect the adj. EBIT margin to contract by ~20 bps Y/Y to 6.9%, balancing lower volumes with positive seasonality effects and contributions from operational improvements undertaken since Q4(23).

Sentiment survey once again indicating a cautious market

In September we surveyed sentiment among Swedish and Finnish contract manufacturers specialising in electronics and mechanics. Similar to the survey we conducted ahead of the Q2 reporting season, the results again illustrate a tough market, where seven out of ten respondents said they had seen activity decline on an annual basis during the third quarter: more than half in the range of -5 to -20%. In addition, sentiment around the market development on a 6-12-month horizon also worsened during the quarter.

Adj. EBIT(24e) impacted by lower margin assumptions

Ahead of the Q3 report we have lowered our margin expectations for 2024e, primarily stemming from our belief that volatile volume demand will have a negative impact on operational flexibility during H2(24).

Weak momentum, but Scanfil is in a good position

Looking beyond a weak 2024, we apply a medium-term valuation approach on our 2026 estimates and a 9.0–11.0x EV/EBIT(NTM) exit multiple, discounted to the present. Following the minor revisions, we merely fine-tune our fair value range to EUR8.6–10.4 per share (8.7–10.5), corresponding to an EV/EBIT(25e) of 9.2–11.2x. In an industry with a strong correlation between profitability and valuation levels, we believe investors should pay attention to Scanfil's top-tier capital efficiency, strong cash generation, and low indebtedness.

Changes in this rep	ort (E	UR)		Key figures (EUR)	2023	2024e	2025e	2026e	Share	price -	5 Y		
	From	То	Chg	Sales (m)	902	768	813	861					
EPS adj. 2024e	0.66	0.63	-5%	EBITDA (m)	80	69	77	82	12.0				
EPS adj. 2025e	0.71	0.69	-2%	EBIT (m)	61	52	59	63	11.0 - 10.0 -			h	
EPS adj. 2026e	0.76	0.74	-2%	EPS	0.74	0.63	0.69	0.74	9.0			- 11	
Upcoming events				EPS adj.	0.74	0.63	0.69	0.74	8.0 -	A	hu.		A.L
				DPS	0.23	0.22	0.23	0.25	7.0 -	YY	MA	1	W
Q3 Report		25 Oc	t 2024	Sales growth Y/Y	7%	-15%	6%	6%	6.0 -	N.	[#! 	r i	
				EPS adj. growth Y/Y	39%	-16%	10%	7%	5.0	100	ing 1	mh.	(h. 1)
				EBIT margin	6.8%	6.8%	7.2%	7.4%	4.0	1 miles		· · · · · ·	a y
Key facts				P/E adj.	9.8	11.6	10.5	9.8	2.0	•			
No. shares (m)			65.2	EV/EBIT	9.1	8.9	7.8	7.2	Sep	Sep 2020	Sep Se 2021 202	p Sep 22 2023	Sep 2024
Market cap. (USDm)			529	EV/EBITA	9.1	8.9	7.8	7.2	2019	2020	2021 202	22 2023	2024
Market cap. (EURm)			473	EV/EBITDA	7.0	6.7	6.0	5.6			anfil		
Net IB Debt. (EURm)		-7	P/BV	1.8	1.6	1.5	1.3					
Adjustments (EURm)			0	Dividend yield	3.2%	3.1%	3.2%	3.4%		0	MX Helsink	i_PI (Rebas	ed)
EV (2024e) (EURm)			466	FCF yield	9.9%	16.0%	6.6%	5.1%	High/L	ow (I2M)		FI	UR8.6/7
Free float			36.0%	Equity/Total Assets	51.4%	56.6%	57.7%	58.8%	Perf.	3M	6M	12M	YTD
Avg. daily vol. ('000)			13										
Risk			m Risk	ROCE	18.2%	15.0%	15.3%	15.0%	Abs.	-1.9	-13.4	-11.1	-7.3
Fiscal year end			ember	ROE adj.	19.6%	14.7%	14.7%	14.3%	Rel.	-5.6	-19.0	-20.4	-9.7
Share price as of (CE	T) 2	7 Sep 2024	17:29	Net IB debt/EBITDA	0.6	-0.1	-0.2	-0.2					


Source: Carnegie Research, FactSet, Millistream & company data

This report has been commissioned and sponsored by Scanfil. Commissioned research is considered to be marketing communication (i.e. not investment research under MiFID II). This material may be subject to restrictions on distribution in certain areas.

For more information, see disclosures and disclaimers at the end of this report



Performance & Valuation Price relative to market - IY





Technology Hardware & Equipment

Price relative to sector - IY

Scanfil

Source: FactSet

10.5 10.0


9.5

Source: FactSet

S

Adj. EPS expectations -2024e (EUR)

OMX Helsinki_Pl







Carnegie

Consensus

Source: C	arnegie Research	& FactSet	Source: Carnegie Research &						
rs	-		Company miscellane	eous					
)	Capital	Votes	CEO	Christophe Su					
	15.2%	15.2%	CFO	Kai Valo					
	12.6%	12.6%	IR	Pasi Hiedanpää					
	11.7%	11.7%	Phone	+358 848 8211					
	9.9%	9.9%	Web	www.Scanfil.com					
n	5.1%	5.1%	Address	Yritystie 6					
	5.1%	5.1%	City	Siev					

Source: FactSet

Source: Carnegie Research

Company description

Carnegie

Major shareholders

Shareholders (%) Harri Takanen

Jarkko Takanen

Jorma Takanen

Jonna Maria Tolonen

Varikot Oy


Reijo Pöllä

Consensus

With origins dating back to 1976, Scanfil is one of the largest listed contract manufacturers in Northern Europe. Combining both mechanics assembly and industrial electronics, Scanfil aims to be the preferred manufacturing partners for demanding industrial customers in the low/mid-volume, high-mix niche of manufacturing. The company has a global factory footprint, operating facilities in nine countries in Europe, the US, and China. Its customer portfolio primarily includes clients in the Industrial, Energy & Cleantech, and Medtech & Life Sciences niches.

Source: Carnegie Research & FactSet


Scanfil in key charts



We expect an organic sales decline of 14% in 2024, before recovering in 2025–26e


Carneqie

Source: Carnegie Research, Company data



We expect sales growth to return to more normalised levels in 2025–26e, while an uptick in M&A could present upside potential to our explicit estimates

Source: Carnegie Research, Company data




Scanfil: Net sales development by customer segment


Energy & Cleantech sales grew at a CAGR of 33% in 2020–23



We expect Scanfil to reach its long-term adj. EBIT margin of 7–8% in 2025–26e




Source: Carnegie Research, Company data



But we remain somewhat cautious about the company's midpoint adj. EBIT(24e) margin guidance

Source: Carnegie Research, Company data


Scanfil: Financial leverage development 2021-26e



Top-tier cash conversion has built one of the strongest balance sheets in the sector, which we believe should enable a return to M&A in 2025e



Scanfil operations in key charts




Large exposure to structural trends such as the green transition, changing demographics, and a more automated society

Source: Carnegie Research, Company data

Scanfil: Geographical split of 2023 employee base

Favourable footprint Central Europe region, which we find attractive

Scanfil has said it plans to broaden APAC and Americas focus through M&A



Source: Carnegie Research, Company data





Deviation table ahead of the Q3 report

Scanfil	2023				2024			CA	Re	1						
EURm	QI	Q2	Q3	Q4	QI	Q2	Q3a	Q3e	Dev.	Q4e	2021	2022	2023	2024e	2025e	2026e
Net sales	224.6	243.3	212.8	220.8	198.9	195.5		172.8		200.8	696	844	902	768	813	861
Other operating income	0.1	0.2	0.4	0.2	0.1	0.3		0.2		0.2	1.2	0.9	0.9	0.8	0.8	0.9
Change of inventories in production,	1.5	-0.1	2.1	-3.9	0.2	-1.2		-0.6		0.0	3.0	0.3	-0.3	-1.6	0.4	0.4
finished goods, and work in progress	1.5	-0.1	2.1	-3.9	0.2	-1.2		-0.6		0.0	3.0	0.3	-0.3	-1.6	0.4	0.4
Manufacturing for own use	0.0	0.0	0.0	0.0	0.0	0.0		0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0
Expenses	-206.5	-221.2	-195.3	-198.7	-181.5	-175.6		-156.6		-184.2	-644.9	-782.0	-821.7	-697.8	-737.I	-780.3
Depreciation and amortisation	-4.7	-4.7	-4.8	-4.9	-5.0	-5.1		-3.8		-3.0	-15.4	-17.5	-19.1	-16.9	-17.9	-18.9
Adj. EBIT	15.0	17.5	15.2	13.4	12.7	13.9		12.0		13.9	40.3	45.4	61.3	52.5	58.8	63.3
Adj. EBIT margin	6.7%	7.2%	7.1%	6.1%	6.4%	7.1%		6.9%		6.9%	5.8%	5.4%	6.8%	6.8%	7.2%	7.4%
EO	0.0	0.0	0.0	0.0	0.0	0.0		0.0		0.0	-2.4	0.0	0.0	0.0	0.0	0.0
EBIT	15.0	17.5	15.2	13.4	12.7	13.9		12.0		13.9	39.6	45.4	61.3	52.5	58.8	63.3
Net financials	-0.6	0.9	-0.7	0.6	0.2	0.1		0.0		0.0	-1.9	-3.7	0.3	0.3	-1.0	-1.3
РТР	14.5	18.4	14.6	14.1	12.9	14.0		12.0		13.9	37.7	41.7	61.6	52.8	57.8	62.0
Tax	-2.8	-3.9	-3.5	-3.2	-3.1	-3.1		-2.6		-3.1	-7.9	-6.7	-13.4	-11.9	-12.7	-13.6
Tax rate	-19%	-21%	-24%	-23%	-24%	-22%		-22%		-22%	-21%	-16%	-22%	-23%	-22%	-22%
Net profit	11.8	14.5	11.0	10.9	9.8	10.8		9.4		10.8	29.8	35.0	48.2	40.9	45.1	48.4
Reported EPS	0.18	0.22	0.17	0.17	0.15	0.17		0.14		0.17	0.46	0.53	0.74	0.63	0.69	0.74
Adj. EPS	0.18	0.22	0.17	0.17	0.15	0.17		0.14		0.17	0.49	0.53	0.74	0.63	0.69	0.74
										-						
Earnings																
EBITDA	19.7	22.2	20.0	18.3	17.7	19.0		15.8		16.9	55.0	62.8	80.4	69.4	76.7	82.3
EBIT	15.0	17.5	15.2	13.4	12.7	13.9		12.0		13.9	39.6	45.4	61.3	52.5	58.8	63.3
PTP	14.5	18.4	14.6	14.1	12.9	14.0		12.0		13.9	37.7	41.7	61.6	52.8	57.8	62.0
Net profit	11.8	14.5	11.0	10.9	9.8	10.8		9.4		10.8	29.8	35.0	48.2	40.9	45.I	48.4
Growth																
Sales growth Y/Y	14.2%	14.3%	0.4%		-11.4%			-18.8%		-9.0%	16.9%	21.3%	6.9%	-14.8%	5.8%	6.0%
- o/w organic	14.9%	16.9%	4.7%		-10.2%			-19.0%		-8.6%	16.5%	18.7%	9.4%	-14.4%	5.8%	6.0%
- o/w structural	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		0.0%		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
- o/w currency	-0.6%	-2.7%	-4.3%	-2.4%	-1.2%	-0.3%		0.2%		-0.5%	0.4%	2.5%	-2.5%	-0.5%	0.0%	0.0%
EBIT growth	45.6%	73.3%	32.2%	0.0%	-15.3%	-20.6%		-21.1%		3.5%	-10.8%	14.6%	35.1%	-14.4%	12.1%	7.6%
Margins																
EBITDA margin	8.8%	9.1%	9.4%	8.3%	8.9%	9.7%		9.1%		8.4%	7.9%	7.4%	8.9%	9.0%	9.4%	9.6%
EBIT margin	6.7%	7.2%	7.1%	6.1%	6.4%	7.1%		6.9%		6.9%	5.7%	5.4%	6.8%	6.8%	7.2%	7.4%
PTP margin	6.5%	7.6%	6.9%	6.4%	6.5%	7.2%		6.9%		6.9%	5.4%	4.9%	6.8%	6.9%	7.1%	7.2%
	0.578		0.770	5.176	0.070			5.770		0.770	5.176				esearch Con	




Insights from Q3 market survey

During Q3, we have conducted a digital survey among unlisted Swedish and Finnish contract manufacturers. Focusing on companies working primarily in the electronics and mechanics niches, the scope of the survey was split to gain a better understanding the current state of business activity and of the prospects ahead. In general, we believe the results confirm the expectation of any rebound in European industrial demand rather belonging to H1(25). For Scanfil, we estimate a return to organic growth in 2025 following an "improvement" in terms of organic declines during H2(24), with significant improvements Q/Q in Q4e (-9% vs. -19% in Q3e). For 2025–26e, we model organic sales growth of ~6% respectively, supported by European industrial demand improving, customer destocking coming to an end and the mechanical effect of easier Y/Y comparisons.



Scanfil: Sales growth development 2021-26e

Looking at the results of the survey, we believe the notion that Nordic contract manufacturers have continued to face a difficult market during Q3 is reinforced. Among the participating companies, about seven out of ten claimed to have seen a decrease in activity versus Q3(23). This is very close to the answers collected when we performed the same survey ahead of the Q2 reporting season. In Q2, the median decline among the companies reporting on organic growth was 8%. Concerning any sequential change Q/Q, responses are more mixed, with about of the respondent group estimating activity to have improved since Q2(24), and the other half not.




In terms of the outlook for the next six and twelve months, we argue that Nordic contract manufacturers have become somewhat more cautious around a potential market recovery. While about half of respondents remain positive about activity improving in the next six months, the share of people now believing it might even become worse before it turns around has increased

Source: Carnegie Research, Company data



since we last conducted this survey, both for the six-and twelve-month horizon.



In the figure below, we have compared the outlook comments from our Q2 survey to the new ones collected ahead of the Q3 reporting season.

Manufacturing demand development	6m fo	rward		l 2m fo	orward	
	Q2(24)	Q3(24)	Change in sentiment	Q2(24)	Q3(24)	Change in sentiment
Better	71%	54%	-	86%	69%	-
Unchanged	21%	23%		14%	16%	
Worse	7%	23%	•	0%	15%	•

Source: Carnegie Research

New reporting structure as of 2025

In a press release sent out 10 September Scanfil announced that it will change the structure of its reporting segments. Starting January 2025, the company will have four reporting segments based on regions: APAC, North Europe, Central Europe, and the Americas. Each region will be managed by an announced VP, who as of 1 January 2025 also will be part of the group's management team. All with an aim to improve transparency, the company will still report on the split between its three customer segments Industrial, Energy & Cleantech, and Medtech & Life Science.

According to the CEO, the announced changes are being made in order to accelerate the company's growth journey, with the aim that regionality will bring added value both in M&A processes and new customer acquisition. For a company striving towards reinitiating its inorganic growth vertical, we believe this move makes sense, where the regional vice president, to our understanding, will lead the M&A pipeline with HQ providing resources as cases mature. In the table below, we have attempted some short headline information regarding each new regional segment. The employee split numbers are as of Q2(24).


Segment	Country footprint	Facility footprint	Employee split
APAC	China	Suzhou	16%
North Europe	Sweden, Finland, Estonia	Åtvidaberg (SE), Malmö (SE), Sievi (FI), Pärnu (EE)	35%
Central Europe	Poland, Germany	Myslowice (PL), Sieradz (PL), Wutha (DE)	44%
Americas	USA	Atlanta	5%

Source: Carnegie Research, Company data

Not out of the woods yet – we model a 19% organic decline in Q3(24)

Ahead of the Q3 report, we have made some changes to our underlying estimates for 2024–26e. We continue to expect Scanfil to report of weak sentiment within its Industrial segment, which in Q2 saw sales drop by 19% following high levels of market uncertainty and lingering effects from destocking. At the same time, we have observed some positive signs within the Medtech & Life science – a theme we also noted in our manufacturing survey for Q3. In the survey, Medtech was recurringly mentioned as a market segment that stood out on the positive side. Still, we believe






that customers in a broad range of sectors remain uncertain, and with difficulties to predict shortterm demand. Thus, we expect sales to continue to decline organically in H2(24) and model a 19% organic sales decline and net sales of EUR173m in Q3(24).

Source: Carnegie Research, Company data

While lower volumes can generally be expected during the third quarter following summer vacations, our net sales estimate for Q3(24) would represent the lowest quarterly sales number since Q3(21). On profitability, we expect margins to contract \sim 20bps Y/Y and Scanfil reporting an adj. EBIT margin of 6.9% in Q3(24). While we continue to model a quite significant volume drawdown, Scanfil has for two quarters in a row now illustrated that the efficiency improvement project initiated at the end of 2023 is starting to pay off, increasing our confidence in Scanfil's ongoing margin journey. Still, we believe that Scanfil during H2(24) will face a larger mismatch in customer demand as some customers start improving volumes while other continue to decrease. Thus, we do not expect the positive margin improvement trend of H1(24) to continue. The third quarter has been the most profitable one for the company historically, with Scanfil during 2016-23 on average reporting an adj. EBIT margin in Q3 that was 60-110bps above the rest.





Source: Carnegie Research, Company data

Based in our expectation that the market situation for the Nordic contract manufacturing industry will remain tricky throughout 2024e, we do not expect Scanfil to return to organic growth until 2025e.

For 2024, we model net sales to reach EUR768m, 2% below the lower end of the company's sales guidance, as we remain cautious about the recovery of European industrial markets. Note that the Industrial segment has accounted for around half of Scanfil's sales in recent quarters. For the full year, we thus expect Scanfil to report an organic sales decline of $\sim 14\%$.



Scanfil

P&L (EURm)	Q1(24)	Q2(24)	Q3(24e)	Q4(24e)	2021	2022	2023	2024e	2025e	2026e
Net sales	198.9	195.5	172.8	200.8	695.7	843.7	901.6	768.0	812.5	861.3
Other operating income	0.1	0.3	0.2	0.2	1.2	0.9	0.9	0.8	0.8	0.9
Change of inventories in production,										
finished goods, and work in progress	0.2	-1.2	-0.6	0.0	3.0	0.3	-0.3	-1.6	0.4	0.4
Manufacturing for own use	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Expenses	-181.5	-175.6	-156.6	-184.2	-644.9	-782.0	-821.7	-697.8	-737.1	-780.3
Depreciation and amortisation	-5.0	-5. I	-3.8	-3.0	-15.4	-17.5	-19.1	-16.9	-17.9	-18.9
Adj. EBIT	12.7	13.9	12.0	13.9	42.0	45.3	61.3	52.5	58.8	63.3
EO	0.0	0.0	0.0	0.0	-2.4	0.0	0.0	0.0	0.0	0.0
EBIT	12.7	13.9	12.0	13.9	39.6	45.3	61.3	52.5	58.8	63.3
Net financials	0.2	0.1	0.0	0.0	-1.9	-3.7	0.3	0.3	-1.0	-1.3
РТР	12.9	14.0	12.0	13.9	37.7	41.7	61.6	52.8	57.8	62.0
Tax	-3.1	-3.1	-2.6	-3. I	-7.9	-6.7	-13.4	-11.9	-12.7	-13.6
Net profit	9.8	10.9	9.4	10.8	29.8	35.0	48.2	40.9	45.I	48.4

Source: Carnegie Research for forecasts, company data for historical numbers

However, we are becoming more and more confident in the company's long-term margin performance and resilience, stemming from an increasing focus on operational efficiency now starting to become visible in reported numbers. In 2024, we expect Scanfil to report an adj. EBIT margin of 6.8%. As volumes and utilisation improve in 2025–26e, we see further opportunities for Scanfil to improve its margin profile even more in its long-term margin target range of 7–8%.

Growth	Q1(24)	Q2(24)	Q3(24e)	Q4(24e)	2021	2022	2023	2024e	2025e	2026e
Sales growth	-11%	-20%	-19%	-9 %	17%	21%	7%	-15%	6%	6%
- o/w organic	-10%	-19%	-19%	-9 %	16%	19%	9 %	-14%	6%	6%
- o/w structural	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
- o/w FX	-1%	0%	0%	-1%	0%	3%	-3%	0%	0%	0%
Adj. EBIT growth	-15%	-21%	-21%	4%	3%	13%	35%	-14%	12%	8%
PTP growth	-11%	-24%	-18%	-2%	-10%	11%	48%	-14%	10%	7%
					Source: Carnegie Res	earch for fo	recasts, con	npany data	for historical	numbers

Margins	Q1(24)	Q2(24)	Q3(24e)	Q4(24e)	2021	2022	2023	2024e	2025e	2026e
EBITDA margin	8.9%	9.7%	9.1%	8.4%	7.9%	7.4%	8.9%	9.0%	9.4%	9.6%
Adj. EBIT margin	6.4%	7.1%	6.9%	6.9%	6.0%	5.4%	6.8%	6.8%	7.2%	7.4%
EBIT margin	6.4%	7.1%	6.9%	6.9%	5.7%	5.4%	6.8%	6.8%	7.2%	7.4%
PTP margin	6.5%	7.2%	6.9%	6.9%	5.4%	4.9%	6.8%	6.9%	7.1%	7.2%

Source: Carnegie Research for forecasts, company data for historical numbers

In the figure below, we have included the underlying changes our estimates for 2024-26e ahead of the report release on 25 October.






Scanfil		2024e			2025e			2026e	
EURm	Old	New	% change	Old	New	% change	Old	New	% change
Net sales	780.4	768.0	-2%	828.0	812.5	-2%	876.1	861.3	-2%
Other operating income	0.8	0.8	-2%	0.8	0.8	-2%	0.9	0.9	-2%
Change of inventories in production, finished goods, and work in progress	-1.6	-1.6	-2%	0.4	0.4	-2%	0.4	0.4	-2%
Manufacturing for own use	0.0	0.0	0%	0.0	0.0	0%	0.0	0.0	0%
Expenses	-707.4	-697.8	-1%	-750.9	-737.1	-2%	-793.3	-780.3	-2%
Depreciation and amortisation	-17.2	-16.9	-2%	-18.2	-17.9	-2%	-19.3	-18.9	-2%
EBIT adj.	55.0	52.5	-5%	60.2	58.8	-2%	64.8	63.3	-2%
EO	0.0	0.0	0%	0.0	0.0	0%	0.0	0.0	0%
EBIT	55.0	52.5	-5%	60.2	58.8	-2%	64.8	63.3	-2%
Net financials	0.3	0.3	0%	-1.0	-1.0	0%	-1.3	-1.3	0%
РТР	55.3	52.8	-5%	59.2	57.8	-2%	63.5	62.0	-2%
Tax	-12.4	-11.9	-4%	-13.0	-12.7	-2%	-14.0	-13.6	-2%
Net profit	42.9	40.9	-5%	48.2	48.2	0%	49.6	48.4	-2%
Reported EPS	0.66	0.63	-5%	0.71	0.69	-2%	0.76	0.74	-2%
Adj. EPS	0.66	0.63	-5%	0.71	0.69	-2%	0.76	0.74	-2%

Source: Carnegie Research




Fair value range lowered to EUR8.6-10.4 (8.7-10.5) per share

In our valuation of Scanfil, we apply a medium-term approach due to the cyclical nature of some of the company's end-markets, and to look beyond the demand weakness we expect in 2024. Our financial expectations for 2026e form the basis of our valuation methodology and we apply a 9.0–11.0x EV/EBIT exit multiple range; the company's historical average is 10.3x. On our updated estimates, we merely fine-tune our fair value range to EUR8.6–10.4 per share (8.7–10.5). Note that any potential contribution from M&A is excluded from our estimates, and that this would present upside to our sales and earnings forecasts. Still, we believe the chances of Scanfil conducting M&A in 2024e are slim following the recently reinitated focus on rebuilding the internal M&A organisation.



Scanfil has historically traded at a slight discount to its Nordic and European peers, which we think is reasonable considering its lower margin profile and historically above-average customer concentration. While we find that the customer concentration risk in Scanfil has diminished significantly in recent years, we believe the discount is likely to remain until Scanfil is able to show EBIT margins in the upper end of its 7–8% target range. On this note, we view the margin result of 7.1% in Q2(24) as supportive.

For 2026e, we model sales of EUR861m, sales growth of 6.0% and an adj. EBIT margin of 7.4%. Depending on order momentum and earnings trends, we believe there are likely re-rating scenarios for the Scanfil share. Moreover, we believe the capital markets currently underappreciate the M&A potential enabled by the company's strong balance sheet, solid capital turnover and attractive cash conversion capabilities. Thus, we value Scanfil using a set of different exit multiples of 9.0–11.0x, yielding a fair value range of EUR8.6–10.4 per share (8.7–10.5). Our fair value range corresponds to an EV/EBIT(25e) of 9.2–11.2x, P/E(25e) of 12.4–15.0x, and an FCF(25e) yield of 4.6–5.6%.



Source: Carnegie Research

To illustrate the potential impact on Scanfil's share price of an improved margin profile for the group, we have in the two tables below illustrated the valuation's inherent sensitivity to changes in EBIT margin assumptions and the exit multiple chosen by the company. Were Scanfil to reach the upper levels of its long-term target of an adj. EBIT margin of 7-8%, we believe a higher fair value range would be warranted both from the perspective of higher earnings and a higher multiple.

	EBIT marg	in 2026e							EBIT margin 2026e								
		6.4%	6.7%	7.1%	7.4%	7.7%	8.0%	8.3%			6.5%	6.8%	7.1%	7.4%	7.7%	8.0%	8.3%
	7.0x	6.1	6.3	6.6	6.8	7.1	7.3	7.6		6.8%	8.6	9.0	9.3	9.7	10.1	10.4	10.8
	8.0x	6.8	7.1	7.4	7.7	8.0	8.3	8.6	e	7.3%	8.5	8.9	9.3	9.6	10.0	10.4	10.
[9.0x	7.6	7.9	8.3	8.6	8.9	9.2	9.6	rat	7.8%	8.5	8.9	9.2	9.6	9.9	10.3	10.
	10.0x	8.4	8.7	9.1	9.5	9.8	10.2	10.5	nut	8.3%	8.4	8.8	9.2	9.5	9.9	10.2	10.
	11.0x	9.2	9.6	10.0	10.4	10.7	11.1	11.5	isco	8.8%	8.4	8.8	9.1	9.5	9.8	10.2	10.
	12.0x	9.9	10.4	10.8	11.2	11.7	12.1	12.5	۵	9.3%	8.4	8.7	9.1	9.4	9.8	10.1	10.
	13.0x	10.7	11.2	11.6	12.1	12.6	13.1	13.5		9.8%	8.3	8.7	9.0	9.4	9.7	10.1	10

Source: Carnegie Research

We have also included a sensitivity table illustrating the impact of different discount rates and exit multiples.

Sensitivity table (iii) - Valuation per share on discount rate vs. Exit multiple
Discount rate

	Discountra	ite						
		6.8%	7.3%	7.8%	8.3%	8.8%	9.3%	9.8 %
	7.0x	6.9	6.9	6.9	6.8	6.8	6.7	6.7
iple	8.0x	7.8	7.8	7.7	7.7	7.7	7.6	7.6
multiple	9.0x	8.7	8.7	8.6	8.6	8.5	8.5	8.4
Ĕ	10.0x	9.6	9.6	9.5	9.5	9.4	9.4	9.3
EV/EBIT	.0x	10.5	10.5	10.4	10.4	10.3	10.2	10.2
EV	l 2.0x	11.4	11.4	11.3	11.2	11.2	11.1	11.0
	13.0x	12.3	12.3	12.2	12.1	12.0	12.0	11.9
						<u> </u>	6	· •

Source: Carnegie Research

Risks

Below we have highlighted some potential risks we see in Scanfil's investment case.

Intense competition

Scanfil may boast decade-long relationships with some of its customers, but competition in the contract manufacturing industry is still intense. If Scanfil were to become unable to meet its customers' demands in factors such as quality, reliability, and pricing, this could impact demand for its services.

Quality issues

As highlighted above, we believe quality is one of the key factors considered by Scanfil's customers. The company measures quality as defective parts per million, and states that the metric improved significantly in 2023. If concerns were to arise regarding the quality of the services offered by Scanfil, this could not only damage the company's financial development, but also its brand as a trusted manufacturing partner.

Customer concentration

In all businesses, there is an inherent risk that one or more customers outgrow other accounts to the extent that the customer portfolio becomes imbalanced. Thus, there is a risk that if one or more of Scanfil's larger customers were to reduce their order levels, it could have an adverse effect on the group's sales and earnings. In 2023, Scanfil's largest customer accounted for 13% of group sales, and the top ten cumulatively comprised 55% of sales. While we note that diversification has increased since the beginning of the 2010s, there is still a risk that a downturn in the largest customers' end-markets could have an adverse effect on Scanfil's bottom line.

farnegie



Inherent industrial cyclicality

In our view, while Scanfil enjoys favourable exposure to structurally growing markets such as industrial electrification and medical technology, contract manufacturing remains a cyclical business niche to some extent. As such, weakening industrial demand and demand for investment goods might have a negative impact on Scanfil's operations. This could in turn lead to overcapacity among the company's production sites, weighing on utilisation rates and ultimately on earnings



Financial statements

Profit & loss (EURm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Sales	530	563	579	595	696	844	902	768	813	861
COGS	-368	-383	-390	-410	-491	-610	-632	-553	-583	-618
Gross profit	162	180	190	185	204	233	270	215	229	244
Other income & costs	-122	-133	-137	-125	-149	-171	-190	-146	-152	-161
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	40	47	53	60	55	63	80	69	77	82
Depreciation PPE	-7	-8	-8	-9	-9	-11	-12	-10	-11	-11
Depreciation lease assets	0	0	-4	-4	-4	-4	-5	-4	-4	-4
Amortisation development costs	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	-2	-2	-2	-3	-3	-3	-3	-3	-3	-3
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	31	38	39	44	40	45	61	52	59	63
Amortization acquisition related	0	0	-4	0	0	0	0	0	0	0
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	31	38	35	44	40	45	61	52	59	63
Share in ass. operations and JV	0	0 -2	0 - I	0 -3	0 -2	0 -4	0 0	0 0	0 -1	0 - I
Net financial items of which interest income/expenses	0	-2	-1	-3	-2	-4	0	0	-1	-1
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	33	36	34	42	38	42	62	53	58	62
Taxes	-7	-7	-6	-5	-8	-7	-13	-12	-13	-14
Post-tax minorities interest	-,	-/	-0	-5	-0	-/	0	-12	-15	-14
Discontinued operations	ő	ő	ő	Ő	ů 0	ő	ő	ŏ	ŏ	Ő
Net profit	26	29	28	37	30	35	48	41	45	48
Adjusted EBITDA	40	47	57	55	56	63	80	69	77	82
Adjusted EBITA	31	38	43	39	40	45	61	52	59	63
Adjusted EBIT	31	38	39	39	40	45	61	52	59	63
Adjusted net profit	26	29	36	32	30	35	48	41	45	48
Sales growth Y/Y	4.3%	6.3%	2.9%	2.7%	16.9%	21.3%	6.9%	-14.8%	5.8%	6.0%
EBITDA growth Y/Y	120.3%	18.0%	12.1%	14.0%	-8.9%	14.0%	27.9%	-13.5%	10.6%	7.2%
EBITA growth Y/Y	332.3%	20.8%	3.1%	13.9%	-10.8%	14.6%	35.1%	-14.4%	12.1%	7.6%
EBIT growth Y/Y	332.3%	20.8%	-6.4%	25.5%	-10.8%	14.6%	35.1%	-14.4%	12.1%	7.6%
EBITDA margin	7.6%	8.4%	9.1%	10.1%	7.9%	7.4%	8.9%	9.0%	9.4%	9.6%
EBITA margin	5.9%	6.7%	6.7%	7.5%	5.7%	5.4%	6.8%	6.8%	7.2%	7.4%
EBIT margin	5.9%	6.7%	6.1%	7.5%	5.7%	5.4%	6.8%	6.8%	7.2%	7.4%
Tax rate	-20.8%	-19.8%	-17.5%	-11.7%	-21.0%	-16.0%	-21.7%	-22.5%	-22.0%	-22.0%
	I.	I.	I.		1		I			
Cash flow (EURm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
EBITDA	40	47	53	60	55	63	80	69	77	82
Paid taxes	-8	-7	-8	-7	-11	-4	-9	-12	-13	-14
Change in NWC	-6 5	-10 2	-8	-8	-53	-43 5	-3	45	-1	-10
Non cash adjustments	5	2	1 0	10 0	4 0	5	-1 0	11 0	15 0	16 0
Discontinued operations Total operating activities	21	29	36	35	-13	10	69	92	48	42
Capex tangible assets	-11	-9	-10	-5	-12	-17	-19	-15	-16	-17
Capitalised development costs	0	0	0	0	0	0	0	0	0	0
Capex - other intangible assets	0	0	-7	0	-1	0	-2	-1	-1	-1
Acquisitions/divestments	0	0	-8	13	0	0	0	0	0	0
Other non-cash adjustments	-!	-	7	-4	1	-2	-1	0	0	0
Total investing activities	-11	-10	-18	4	-13	-19	-22	-16	-17	-18
Net financial items	I	-2	-1	-3	-2	-4	0	0	-1	-1
Lease payments	0	0	0	-4	-4	-4	-4	-4	-4	-4
Dividend paid and received	-6	-7	-8	-10	-11	-12	-14	-15	-15	-15
Share issues & buybacks	0	0	0	I	0	0	0	0	0	0
Change in bank debt	-4	-14	-8	-20	38	20	-30	-6	0	0
Other cash flow items Total financing activities	0 -11	0 - 22	0 -18	0 - 34	23	0 2	ا -50	0 - 25	0 - 20	0 - 21
-	-11	-22	-16	35	-13		- 30 69	-23 92	-20 48	- 21 42
Operating cash flow Free cash flow	21	29 19	36	35 26	-13	10 -8	69 47	92 76	48 31	42 24
	2	-1	26 		-25 -1	-8 -4	4/ 	76 51	13	24 5
Net cash flow Change in net IB debt	2 3	-1	17	6 28	-1	-4	35	51	13	5
Capex / Sales	2.0%	1.6%	1.7%	0.8%	1.8%	2.0%	2.1%	2.0%	2.0%	2.0%
NWC / Sales	17.2%	17.6%	19.2%	19.8%	20.7%	22.8%	23.8%	25.3%	21.1%	20.6%



Financial statements, cont.

Balance sheet (EURm)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Acquired intangible assets	10	10	8	8	8	8	8	8	8	8
Other fixed intangible assets	15	12	17	14	13	11	10	8	6	3
Capitalised development	0	0	0	0	0	0	0	0	0	0
Tangible assets	48	49	72	65	72	80	85	91	99	108
Lease assets	0	0	21	18	22	24	23	23	25	28
Other IB assets (1)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	4	4	6	7	9	8	8	8	8	8
Fixed assets	77	76	103	95	102	107	112	115	121	127
Inventories (2)	101	99	102	103	193	229	209	167	167	176
Receivables (2)	106	108	112	113	149	165	174	149	160	172
Prepaid exp. & other NWC items (2)	i i	0	1	í	i i	2	1	i i	1	1
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	i	2	2	2	3	2	2	9	25	40
Cash & cash equivalents (1)	21	19	20	26	25	21	21	75	85	89
Current assets	230	228	237	245	372	419	406	401	438	478
Total assets	307	304	340	339	474	526	518	516	558	605
Shareholders' equity	125	145	167	183	207	227	266	292	323	356
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	125	145	167	183	207	227	266	292	323	356
Deferred tax	5	6	7	6	5	5	6	7	7	7
LT IB debt (I)	27	17	25	18	42	36	0	30	30	30
Other IB provisions (1)	0	0	0	0	0	0	0	0	0	0
Lease libilities	0	0	19	16	20	20	19	18	20	22
Other non-IB liabilities	0	0	0	I	I	I	I	I	I	I
LT liabilities	33	23	51	40	68	62	25	56	58	60
ST IB debt (I)	34	31	23	10	23	50	54	20	20	21
Payables (2)	113	104	96	100	172	184	167	146	155	166
Accrued exp. & other NWC items (2)	0	0	0	0	0	0	0	0	0	0
Other ST non-IB liabilities	2	2	3	6	3	4	5	3	3	3
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	149	136	122	116	198	237	227	169	178	190
Total equity and liabilities	307	304	340	339	474	526	518	516	558	605
• •	41	28	46	18	60	86	52	-7	-15	17
Net IB debt $(=1)$	41									-17
Net working capital (NWC) (=2)	95	104	118	117	171	213	217	171	172	183
Capital employed (CE)	191	198	237	229	295	334	342	362	395	430
Capital invested (CI)	166	173	213	201	267	312	318	284	308	339
Equity / Total assets	41%	48%	49%	54%	44%	43%	51%	57%	58%	59%
Net IB debt / EBITDA	1.0	0.6	0.9	0.3	1.1	1.4	0.6	-0.1	-0.2	-0.2
Per share data (EUR)	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
Adj. no. of shares in issue YE (m)	63.76	63.95	64.30	64.39	64.70	64.83	64.86	65.19	65.19	65.19
Diluted no. of Shares YE (m)	64.47	64.48	65.13	65.19	65.33	65.74	64.86	65.19	65.19	65.19
EPS	0.40	0.45	0.43	0.57	0.46	0.53	0.74	0.63	0.69	0.74
	0.40	0.45	0.43		0.48		0.74	0.63	0.69	0.74
EPS adj.				0.48		0.53				
CEPS	0.54	0.60	0.71	0.75	0.63	0.74	0.97	0.83	0.90	0.97
DPS	0.11	0.13	0.15	0.17	0.19	0.21	0.23	0.22	0.23	0.25
BVPS	1.96	2.26	2.59	2.84	3.21	3.50	4.10	4.48	4.95	5.46
Performance measures	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
ROE	22.2%	21.4%	18.0%	21.1%	15.2%	16.1%	19.6%	14.7%	14.7%	14.3%
Adj. ROCE pre-tax	16.4%	19.0%	16.6%	17.0%	13.6%	13.6%	17.9%	14.5%	14.9%	14.7%
Adj. ROIC after-tax	14.8%	17.7%	15.7%	17.0%	12.1%	12.4%	15.1%	14.3%	15.0%	14.6%
Valuation	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
FCF yield	2.3%	4.1%	5.4%	5.5%	-5.3%	-1.7%	9.9%	16.0%	6.6%	5.1%
Dividend yield YE	2.5% na	na	3.1%	2.6%	2.5%	3.1%	2.9%	3.1%	3.2%	3.4%
Dividend payout ratio	27.4%	29.0%	34.6%	30.2%	41.7%	38.8%	31.0%	35.5%	33.3%	33.3%
Dividend + buy backs yield YE	na	na	3.0%	2.6%	2.5%	3.1%	3.0%	3.1%	3.2%	0.0%
EV/Sales YE	na	na	0.63	0.74	0.79	0.61	0.62	0.61	0.56	0.53
EV/EBITDA YE	na	na	6.9	7.3	10.0	8.3	7.0	6.7	6.0	5.6
EV/EBITA YE	na	na	9.4	10.0	13.8	11.4	9.1	8.9	7.8	7.2
EV/EBITA adj. YE	na	na	8.5	11.4	13.6	11.5	9.2	8.9	7.8	7.2
EV/EBIT YE	na	na	10.3	10.0	13.8	11.4	9.1	8.9	7.8	7.2
P/E YE	na	na	11.3	11.5	16.4	12.3	10.5	11.6	10.5	9.8
P/E adj. YE	na	na	10.0	13.5	15.2	12.3	10.5	11.6	10.5	9.8
P/BV YE	na	na	1.89	2.30	2.33	12.5	1.91	1.62	1.47	1.33
	11a	114							1.17	1.55
Share price YE (EUR)			4.89	6.52	7.46	6.58	7.83	7.26		



Disclosures and disclaimers

Carnegie Investment Bank AB

Carnegie Investment Bank AB (publ.) is a leading investment bank with a Nordic focus. The Carnegie group of companies, together "Carnegie", generates added value for institutions, companies and private clients in the areas of trade in securities, investment banking and private banking. Carnegie has approximately 600 employees, located in offices in six countries

Valuation, methodology, and assumptions

Commissioned research reports include the analyst's assessment of a fair value range over the coming six to 12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E ratio and EV/EBIT multiples, relative to industry peers to obtain a target price. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing

Frequency of update

Carnegie's research analysis consists of case-based analyses, which implies that the frequency of the analytical report may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Analyst certification

The research analyst or analysts responsible for the content of this commissioned research report certify that, notwithstanding the existence of any potential conflicts of interests referred to herein, the views expressed in this commissioned research report accurately reflect the research analyst's personal views about the companies and securities covered. It is further certified that the research analyst has not been, nor is or will be, receiving direct or indirect compensation related to the specific ratings or views contained in this commissioned research report.

Potential conflicts of interest

Carnegie, or its subsidiaries, may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this report. Any such publicly announced business activity, during the past 12 months, will be referred to in this commissioned research report. A set of rules handling conflicts of interest is implemented in the Carnegie Group. Investment Banking and other business departments in Carnegie are surrounded by information barriers to restrict the flows of sensitive information. Persons outside such barriers may gain access to sensitive information only after having observed applicable procedures. The remuneration of persons involved in preparing this commissioned research report is not tied to investment banking transactions performed by Carnegie or a legal person within the same group.

Confidential and non-public information regarding Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner.

Internal guidelines are implemented in order to ensure the integrity and independence of research analysts. In accordance with the guidelines the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues; contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines and analyst remuneration.

Other material conflicts of interest

This report was commissioned and sponsored by the issuer (issuer-paid research).

Distribution restrictions

This commissioned research report is intended only for distribution to professional investors. Such investors are expected to make their own investment decisions without undue reliance on this commissioned research report. This commissioned research report does not have regard to the specific investment objectives, financial situation or particular needs of any specific person who may receive it. Investors should seek financial advice regarding the appropriateness of investing in any securities discussed in this commissioned research report and should understand that statements regarding future prospects may not be realized. Past performance is not necessarily a guide to future performance. Carnegie and its subsidiaries accept no liability whatsoever for any direct or consequential loss, including, without limitation, any loss of profits arising from the use of this commissioned research report or its contents. This commissioned research report may not be reproduced, distributed or published by any recipient for any purpose. The document may not be distributed to persons that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.

This commissioned research report is distributed in Sweden by Carnegie Investment Bank AB. Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability which is authorised and regulated by the Swedish Financial Supervisory Authority (Finansinspektionen). In Finland this commissioned research report is issued by Carnegie Investment Bank AB, Finland Branch. The Finland branch is authorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Finnish Financial Supervisory Authority (Finanssivalvonta). In Norway this commissioned research report is issued by Carnegie AS, a wholly-owned subsidiary of Carnegie Investment Bank AB. Carnegie AS is regulated by the Financial Supervisory Authority of Norway (Finanssilsynet). In Denmark this commissioned research report is issued by Carnegie Investment Bank AB, Denmark Branch. The Denmark this cumhorised by the Swedish Financial Supervisory Authority and subject to limited regulation by the Danish Financial Supervisory Authority (Finanstilsynet).

This commissioned research report is distributed in the US by Carnegie, Inc., a US-registered broker-dealer and a member of FINRA and SIPC. Carnegie's research analysts located outside of the US are employed by non-US affiliates of Carnegie Inc. ("non-US affiliates") that are not subject to FINRA regulations. Generally, Carnegie research analysts are not registered with or qualified as research analysts with FINRA, and therefore are not subject to FINRA rule 2241 restrictions intended to prevent conflicts of interest by, among other things, prohibiting certain compensation practices, restricting trading by analysts and restricting communications with the companies that are the subject of the research neport. Research reports distributed in the U.S. are intended solely for major US institutional investors and US institutional investors as defined under Rule ISa-6 of the Securities Exchange Act of 1934. This commissioned research report is provided for informational purposes only and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy any securities. Reports regarding equity products are prepared by non-US affiliates of and distributed in the United States by Carnegie Inc. under Rule ISa-6(a)(3). When distributed by Carnegie Inc, Carnegie Inc, takes responsibility for the commissioned research report. Any US person who wishes to effect transactions based on this commissioned research report should contact Carnegie Inc. Investors and Tshould be aware that investing in non-US securities entails certain risks. The securities of non-US issuers may not be registered with, or be subject to, the current information reporting and audit standards of the US Securities and Exchange Commission. This commissioned research report has been issued in the UK by Carnegie UK which is the UK Branch of Carnegie Investment Bank AB. Carnegie UK is authorised and regulated by the Financial Conduct Authority (FCA).

Research Disclaimer

This commissioned research report is provided solely for information. It does not constitute or form part of, and shall under no circumstances be considered as an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instrument.

This commissioned research report has been requested and paid for by the issuer and should therefore be considered a marketing communication (i.e. not investment research). Payment for the report has been agreed in advance on a non-recourse basis. As commissioned research, this material can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to a prohibition on dealing ahead of the dissemination of the report.

Carnegie Investment Bank AB is responsible for the preparation of this commissioned research report in Sweden, Finland, Denmark, and the UK. Carnegie AS is responsible for the preparation of this commissioned research report in Norway. Carnegie Inc. is responsible for this research report in the US.

The information in this commissioned research report was obtained from various sources. While all reasonable care has been taken to ensure that the information is true and not misleading. Carnegie gives no representation or warranty, express or implied, about its accuracy or completeness. Carnegie, its subsidiaries and any of their officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this commissioned research report. Any significant financial interests held by the analyst, Carnegie or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Company specific disclosures

The following disclosures relate to relationships between Carnegie Investment Bank AB (with its subsidiaries, "Carnegie") and the issuer or an affiliate.

Parts of this commissioned research report may have been submitted to the issuer prior to its publication.

Copyright © 2024 Carnegie



Commissioned Research sponsored by Scanfil

30 September 2024

Carnegie Investment Bank AB	Carnegie Investment Bank, Denmark Branch	Carnegie Investment Bank AB, Finland Branch			
Regeringsgatan 56 SE-103 38 Stockholm	Overgaden neden Vandet 9B PO Box 1935 DK-1414 Copenhagen K	Eteläesplanadi 2 PO Box 36 FI-00131 Helsinki			
Tel +46 8 5886 88 00 Fax +46 8 5886 88 95 www.carnegie.se	Tel +45 32 88 02 00 Fax +45 32 96 10 22 www.carnegie.dk	Tel +358 9 618 71 230 Fax +358 9 618 71 720 www.carnegie.fi			
A member of the Stockholm Stock Exchange	A member of the Copenhagen Stock Exchange	A member of the Helsinki Stock Exchange			
Carnegie AS	Carnegie, Inc.	Carnegie Investment Bank AB, UK Branch			
Fjordalleen 16, 5th Floor PO Box 684,	20 West 55th St. ,	Finwell House, 26 Finsbury Square			
Sentrum NO-0106 Oslo	New York N.Y. 10019	London EC2A IDS			
Tel +47 22 00 93 00 Fax +47 22 00 94 00 www.carnegie.no	Tel +1 212 262 5800 Fax +1 212 265 3946 www.carnegiegroup.com	Tel +44 20 7216 4000 Fax +44 20 7417 9426 www.carnegie.co.uk			
A member of the Oslo Stock Exchange	Member FINRA / SIPC	Regulated by the FCA in the conduct of Designated			

Investment Business in the UK